CMS Considers Coverage For GE’s Risk-Predictor Tool For Sudden Cardiac Death
This article was originally published in The Gray Sheet
The Medicare agency says it is reconsidering a 2008 national noncoverage policy for GE Healthcare’s microvolt T-Wave alternans testing tool for evaluating risk of sudden cardiac death, and the potential need for an ICD. An alternative MTWA technique is already covered, but the company that makes that product is going out of business.
You may also be interested in...
After cardiologists strongly urged CMS to support MWTA testing using the modified moving average method to determine if patients are at risk of sudden cardiac death, CMS left an opening for local Medicare contractors to decide on coverage rather than retaining a national non-coverage policy.
In a new proposed decision memo, CMS says it plans to confirm its existing national non-coverage policy on microvolt T-wave alternans diagnostic testing with the modified moving average method.
Industry and physician stakeholders say CMS missed a key study in considering its coverage policy for noninvasive tests that help assess a patient's need for an implantable defibrillator. Competing test makers have different views on how the new data should be interpreted